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Abstract
An important step in the process of metastasis from the primary tumor is invasive spread into the
surrounding stroma. Using an in vivo invasion assay, we have previously shown that imposed
gradients of EGF or CSF-1 can induce invasion through an EGF/CSF-1 paracrine loop between
cancer cells and macrophages. We now report that invasion induced by other ligands also relies upon
this EGF/CSF-1 paracrine invasive loop. Using an in vivo invasion assay, we show that MTLn3 breast
cancer cells overexpressing ErbB3 exhibit enhanced invasion compared to control MTLn3 cells in
response to the ErbB3 ligand HRG-β1. The invasive response of both MTLn3-ErbB3 and transgenic
MMTV-Neu tumors to HRG-β1 is inhibited by blocking EGFR, CSF-1R, or macrophage function,
indicating that invasiveness to HRG-β1 is dependent upon the EGF/CSF-1 paracrine loop.
Furthermore, we show that CXCL12 also triggers in vivo invasion of transgenic MMTV-PyMT
tumors in an EGF/CSF-1 dependent manner. Although the invasion induced by HRG-β1 or CXCL12
is dependent on the EGF/CSF-1 paracrine loop, invasion induced by EGF is not dependent upon
HRG-β1 or CXCL12 signaling, demonstrating an asymmetric relationship between different ligand/
receptor systems in driving invasion. Our results identify a stromal/tumor interaction that acts as an
engine underlying invasion induced by multiple ligands.
INTRODUCTION
Metastasis is a multi-step process involving invasion of the basement membrane and
surrounding stroma, intravasation, extravasation and survival/growth of cancer cells at new
sites (1). Our research has focused on elucidating what drives cancer cells to leave the primary
tumor, cross the basement membrane, resulting in invasion of the surrounding stroma, with
the expectation of finding novel targets of metastasis that may be used to prevent the occurrence
of this fatal process. With the development of an in vivo invasion assay in which invasive cells
are collected from the primary tumor using needles preloaded with Matrigel and a
chemoattractant (2), new insights into the process of invasion have been made. Employing this
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in vivo invasion assay to collect invasive cells from rat MTLn3 breast primary xenograft tumors
as well as from transgenic mice in which mammary tumors are induced by the expression of
the Polyoma Middle T oncoprotein from the MMTV promoter (PyMT) (3), it was observed
that macrophages aided cancer cells in invading the surrounding tissue. This was due to a
paracrine communication loop involving secretion of CSF-1 by cancer cells that would activate
macrophages to secrete EGF, a chemoattractant for the cancer cells that would drive their
invasion (4). Inhibition of either EGF or CSF-1 signaling resulted in decreased invasion to
background levels (3), suggesting that EGF/CSF-1 signaling was the key to in vivo invasion
in response to either EGF or CSF-1 in this model.
This research implicated the tumor microenvironment, especially stromal cells such as
macrophages, in collaborating in the process of metastasis. Tumor associated macrophages,
TAMs, have been correlated with poor prognosis in several cancers including breast, with high
density of TAMs associated with metastasis (5,6). Furthermore, overexpression of CSF-1, a
major growth factor involved in the survival, differentiation and chemotaxis of macrophages
has been shown to correlate with poor prognosis in breast cancer (7,8). Studies using transgenic
PyMT mice carrying a null mutation in the CSF-1 gene showed that recruitment of
macrophages to the primary tumor was dramatically decreased in this model and accordingly,
there was slower tumor progression with significantly reduced metastasis that was rescued
upon expression of CSF-1 in the mammary tumor epithelium (9). Furthermore, imaging of
PyMT tumors in which macrophages were labeled with Texas Red dextran showed that tumor
cell motility was associated with the presence of macrophages, with more frequent motility
associated with perivascular macrophages (10), suggesting again a close interaction between
carcinoma cells and macrophages within the primary tumor that facilitates invasion.
In vitro characterization of invasion typically involves studying cancer cell traversal of a
Matrigel barrier. Using this assay, several chemoattractants have been found to stimulate
invasion, including CXCL12 (SDF-1) and Heregulin Beta 1 (HRGβ1). CXCL12 is a chemokine
that binds to CXCR4. CXCR4 can be highly expressed on breast cancer cells as compared to
normal breast tissue (11), and has been implicated as a predictor of poor prognosis in patients
with breast cancer (12). In MDA-MB-231 breast cancer cells it has been shown that CXCL12
stimulates their invasion in vitro, as well as plays a key role in the metastatic behavior of these
cells in vivo (11). HRGβ1, an EGF-like ligand that binds and activates ErbB3 and ErbB4,
members of the ErbB family of receptor tyrosine kinases (13), has been implicated in
modulating the invasive behavior of breast cancer cells. HRGβ1 stimulates the in vitro invasive
behavior of MDA-MB-231, and downregulation of HRGβ1 expression results in impaired
invasiveness in vitro and metastasis in vivo (14). HRGβ1 also has been shown to induce the
migration and invasion of MCF-7 and T47D cells in vitro through activation of the ErbB2 and
ErbB3 receptors (15). Overexpression of ErbB3 in MTLn3 cells results in enhanced chemotaxis
to HRGβ1 as well as in increased metastatic behavior of MTLn3 cells, including leaving the
primary tumor in greater numbers (16).
Since CXCL12 and HRGβ1 have been implicated in breast cancer cell invasion, we tested their
ability to stimulate invasion in vivo in the tumor microenvironment using the in vivo invasion
assay. Remarkably, we found that although HRGβ1 can stimulate the in vivo invasion of
MTLn3 cells overexpressing the ErbB3 receptor, this invasion is inhibited by addition of Iressa,
an EGFR tyrosine kinase inhibitor, or an EGF neutralizing antibody, as well as by a CSF-1R
blocking antibody or by macrophage depletion using liposome encapsulated clodronate. This
dependency on EGF/CSF-1 signaling to stimulate invasion in vivo was recapitulated in the
MMTV-Neu transgenic animal model of mammary cancer in which ErbB3 is also expressed
(17). In addition, we found that in vivo invasion towards a G-protein coupled receptor ligand,
CXCL12, is also dependent upon the EGF/CSF-1 paracrine loop. Our results suggest that
targeting EGF or CSF-1 signaling can be effective in blocking invasion in response to
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heterologous ligands through a novel dependence on tumor/stroma interactions revealed in
vivo.
MATERIALS AND METHODS
Cell lines and animal models
All procedures involving mice were conducted in accordance with the National Institutes of
Health regulations concerning the use and care of experimental animals. The study of mice
was approved by the Albert Einstein College of Medicine animal use committee. The rat
mammary carcinoma MTLn3 cells transduced with the empty pLXSN retroviral vector or
vector containing human ErbB3 receptor (16) were grown in α-MEM supplemented with 5%
fetal bovine serum (FBS) and penicillin/streptomycin solution (Life Technologies). The tumor
cells were grown to 70–85% confluence before being harvested. Cells were detached using
PBS-EDTA and 5 scraped using a rubber policeman. 5×105 cells were injected into the right
fourth mammary fat pad from the head of 5-to-7-week-old female severe combined
immunodeficient (SCID) mice (National Cancer Institute, Bethesda, MD). Tumors were
allowed to grow for 4 weeks before cell collection. FVB mice transgenic for the polyoma virus
middle T (PyVT or PyMT) oncogene under the mouse mammary tumor virus (MMTV) long
terminal repeat 206 (LTR), generated as previously described (18), were used for in vivo
invasion assays at 12–14 weeks of age. FVB mice transgenic for Neu driven by the MMTV
LTR containing an activating deletion in the extracellular region (17) were used in in vivo
invasion assays and for primary tumor harvest at 31–33 weeks of age.
In vivo invasion assay
Cell collection into needles placed in the primary tumor of anesthetized mice was carried out
as described previously (2). Invasive cells were collected into 33-gauge Hamilton needles
(Fisher 14-815-423) filled with Matrigel (Beckton Dickinson 356234) diluted 1:10 with L15-
BSA and a chemoattractant for 4 hours. At the end of collection, the contents of the needles
were extruded with approximately 30ul DAPI using a syringe onto a coverslip. The
chemoattractants used in this assay include HRGβ1 at a concentration of 50nM (R & D Systems
396-HB), EGF at 25nM (Life Technologies), and CXCL12α at 62.5nM (R & D Systems 460-
SD). To inhibit activation of the EGF receptor through EGF binding, an anti-mouse EGF
neutralizing antibody (R & D Systems AF2028) was used at a concentration of 20μg/ml. To
inhibit activity of the EGF receptor, Iressa (AstraZeneca), a tyrosine kinase inhibitor specific
for the EGF receptor, was used at 1 μM. For inhibiting the CSF-1 receptor, a purified
monoclonal anti-mouse CSF-1 receptor antibody (AFS98) (19) was used at 15μg/ml. To block
activation of CXCR4, AMD3100 was used at 100nM (Sigma A5602). To block HRGβ1
mediated signaling, an ErbB3 antibody that blocks binding of HRGβ1 to the ErbB3 receptor
was used (Fisher HER-3 Ab-5). As a control antibody for the experiments involving signaling
inhibition using blocking/neutralizing antibodies, a mouse IgG antibody was used at the same
concentration used for the experimental antibodies (Jackson ImmunoResearch 015-000-003).
To functionally impair macrophages in mice bearing tumors, clodronate liposomes were
administered systemically. Empty (control) and clodronate-containing liposomes were
administered by tail vein into mice 48 hours prior to the in vivo invasion assay. Liposomes
were prepared as detailed in (20) using clodronate at a concentration of 2.5 grams per 10 ml
PBS. Clodronate (or Cl2MDP) was a gift of Roche Diagnostics GmbH, Mannheim, Germany.
Phosphatidylcholine (LIPOID E PC) was obtained from Lipoid GmbH, Ludwigshafen,
Germany. Cholesterol was purchased from SIGMA Chem.Co., USA. Animals were injected
with 100μl of liposome solution per 10g of weight.
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Determination of cell types collected in the in vivo invasion assay
After 4 hour collection, the invasive cells were extruded from the needles using 10%
paraformaldehyde into poly-L-lysine coated MatTek dishes and fixed for 1 hour at room temp.
To block non-specific binding the samples were incubated overnight at 4°C in Tris-buffered
saline (TBS)-1% FBS. The blocking solution was removed, cells washed with TBS-1% BSA
and incubated with a primary antibody mixture of mouse anti-ErbB3 antibody (Neomarkers
MS-303) for carcinoma cells and rat anti-F4/80 (21) for macrophages in TBS-1% BSA. After
1 hour incubation with the primary antibodies, the cells were washed with TBS-1% BSA and
incubated in a mixture of goat anti-mouse Cy3 and sheep anti-rat FITC. The cells were rinsed
and left in TBS-1% BSA with 4′,6 -diamidino-2-phenylindole (DAPI) and counted using a
fluorescence microscope.
Microchemotaxis chamber assay
A 48-well microchemotaxis chamber (Neuroprobe, Cabin John, MD) was used as described
previously (16). Briefly, cells were starved for 3 hours in L15 media supplemented with 0.35%
BSA (L15-BSA) at 37°C, then detached using PBS-EDTA and loaded into the top wells of the
microchemotaxis chamber, 20,000 cells per well. Cells were allowed to migrate for 4 hours at
37°C through a collagen-coated 8um pore filter (Neuroprobe) towards bottom wells filled with
either EGF or HRGβ1 diluted in L15-BSA with or without EGF neutralizing antibody (R & D
Systems AF2028), or to L15-BSA alone. The filter was then taken out, fixed in 10%
paraformaldehyde for 1 hour, nonmigrating cells were removed from the top surface of the
filter, and the remaining cells on the lower surface were stained overnight in hematoxylin
staining solution (Fisher, CS402-1D). The membrane was then washed in de-ionized water and
migrated cells were counted using a light microscope.
Primary tumor cell culturing and CSF-1 ELISA
After the animal was euthanized, the primary tumor was removed, rinsed briefly in 70% ethanol
and washed with PBS. In a petri dish with PBS, the tumor was minced until only small clumps
remained. The minced tumor was transferred into a 50 ml conical tube into 10ml digestion
medium consisting of growth medium supplemented with 300 U/ml collagenase (Sigma
C5138) and 100 U/ml hyaluronidase (Sigma H3506), and incubated in a 37°C shaker for 30
mins. Tumor cells and clumps were centrifuged at 1000rpm, washed 3X with PBS and
resuspended in growth medium (DMEM/F12 (Fisher MT10092CV) supplemented with 10%
FBS, and 50U/ml Pen/Strep, 10μg/ml insulin (Sigma I5523), 1mg/ml BSA, 5μg/ml linoleic
acid complex (Sigma L1376), 20U/ml Fungizone (Invitrogen 15290-018), 50μg/ml
Gentamicin (Sigma G-1272), and 1.2g sodium bicarbonate per 1000 ml medium) and plated
at densities varying from 1 to 5 × 106 on 10cm plates (22). The following day the cultures were
washed with growth medium and medium was changed every day following that. Cells were
cultured for 5–10 days before they were used for in vitro stimulations. Cells were grown to
85–90% confluency, starved for 3 hours in L15-BSA and stimulated for 4 hours with 12.5nM
HRGβ1 in L15-BSA. After 4 hours, the supernatants were collected, spun down to remove
debris and stored at −20°C. The samples were tested for the presence of secreted CSF-1 using
a mouse CSF-1 ELISA kit (R & D Systems MMC00).
Statistical analysis
Multiple comparisons were performed using ANOVA and 2 condition comparisons performed
using t-test.
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RESULTS
HRGβ1 stimulates the in vivo invasion of MTLn3-ErbB3 cells
ErbB3 overexpression in MTLn3 cells increases their in vitro chemotactic response to
HRGβ1 through the formation of active ErbB2-ErbB3 heterodimers (16), as well as their
metastatic behavior in vivo. To investigate whether HRGβ1 could also stimulate MTLn3 rat
mammary adenocarcinoma cell chemotaxis and invasion in vivo, cells expressing increased
levels of ErbB3 (MTLn3-ErbB3) or empty vector control cells (MTLn3-pLXSN) were injected
into the mammary fat pads of SCID mice to form orthotopic tumors. Four weeks post-injection,
microneedles containing Matrigel and a chemoattractant were inserted into the primary tumors
to collect invasive cells. HRGβ1 induced in vivo invasion in MTLn3-ErbB3 tumors (Fig. 1A)
in a dose dependent fashion, with the optimal concentration being 50nM HRGβ1. Using EGF
as a chemoattractant, comparable invasiveness of MTLn3-pLXSN and MTLn3-ErbB3 cells
was observed, indicating that overexpression of ErbB3 did not affect the ability of MTLn3
cells to respond to EGF (Fig. 1B). However, MTLn3-ErbB3 tumors showed a greater in vivo
invasion in response to HRGβ1 compared to control pLXSN tumors (Fig 1B).
Previous studies have shown that macrophages co-migrate with breast cancer cells in response
to EGF stimulation in the needle collection assay (3) To assess whether macrophages also co-
migrate with cancer cells in HRGβ1-mediated in vivo invasion, the invasive cells collected
upon HRGβ1 stimulation from MTLn3-ErbB3 tumors were fixed and stained with an ErbB3
antibody to detect MTLn3-ErbB3 cells and an F4/80 antibody to detect macrophages. MTLn3-
ErbB3 cells represented 75% (±5%) of the invasive population and macrophages 25% (±5%),
with no other cell types present in significant amounts, similar to what we have previously
reported for the in vivo invasion in response to EGF (3). To test whether macrophages play a
role in the invasive behavior of MTLn3-ErbB3 cells in response to HRGβ1, macrophages were
functionally impaired using clodronate-containing-liposomes (20). SCID mice bearing
MTLn3-ErbB3 tumors were injected i.v. with clodronate-containing-liposomes or empty
liposomes as a negative control 48 hours prior to performing the in vivo invasion assay. As
described in the Supplemental Data and Supplemental Fig. 1, although the number of
macrophages in the primary tumor is not decreased, clodronate liposome treatment results in
reduced macrophage function as measured by macropinocytosis of 70kD dextran. There was
a significantly reduced invasive response to HRGβ1 in tumors that had been pretreated with
clodronate, compared to those pretreated with empty liposomes (ratio of HRGβ1-induced in
vivo invasion in the presence of clodronate-containing liposomes to empty liposomes: 0.6 ±0.1,
p<0.01); while basal invasion in the absence of attractant was not affected. This indicates that
macrophages contribute to the invasive behavior of MTLn3-ErbB3 cells in response to
HRGβ1 stimulation.
The EGF/CSF-1 paracrine loop is required for the in vivo invasion of MTLn3-ErbB3 cells in
response to HRGβ1
The previous section suggested that macrophages could play an active role in HRGβ1-induced
in vivo invasion of MTLn3-ErbB3 cells. We therefore tested whether the EGF/CSF-1 paracrine
loop was necessary for HRGβ1-induced in vivo invasion. We first evaluated the role of CSF-1
signaling by blocking the CSF-1 receptor on macrophages using a CSF-1 receptor blocking
antibody. As a positive control, we confirmed that the invasion of MTLn3-ErbB3 tumor cells
towards EGF was inhibited upon blockage of the CSF-1 receptor (p<0.05) (Fig. 2A, left side).
Similarly, addition of the CSF-1 receptor antibody also inhibited HRGβ1-stimulated in vivo
invasion by MTLn3-ErbB3 tumors (p<0.005) (Fig. 2A, right side), indicating that activation
of the CSF-1 receptor in macrophages is required for MTLn3-ErbB3 cells to invade in response
to HRGβ1.
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To determine whether EGF signaling also plays a role in the invasive response of MTLn3-
ErbB3 cells to HRGβ1 stimulation, an EGFR- specific tyrosine kinase inhibitor, Iressa (23),
was added to microneedles loaded with HRGβ1 (Fig. 2B). Addition of Iressa inhibited the in
vivo invasion of MTLn3-ErbB3 cells to HRGβ1, bringing the response down to basal levels
(p<0.05). This suggests that EGFR signaling is required for MTLn3-ErbB3 cells to invade
when stimulated with HRGβ1. To test whether EGF specifically was required, we determined
the effect of an EGF antibody that blocks the binding of EGF to its receptor, EGFR (Fig. 2C).
The EGF antibody significantly inhibited the in vivo invasion of MTLn3-ErbB3 cells to EGF
as anticipated (p<0.05, Fig. 2C, left side), but also resulted in inhibition of the in vivo invasion
of MTLn3-ErbB3 cells to HRGβ1 (p<0.005, Fig. 2C, right side). To check that the neutralizing
EGF antibody was specific in blocking EGF-mediated signaling and does not affect HRGβ1
binding and chemotaxis, a Boyden chamber was used to analyze the in vitro chemotaxis
behavior of MTLn3-ErbB3 cells in the presence of the EGF antibody. While the EGF antibody
itself had no effect in the basal motility of MTLn3-ErbB3 cells (p<0.6, data not shown), the
EGF antibody blocked the chemotaxis of MTLn3-ErbB3 cells to EGF (p<0.005) but not to
HRGβ1 (p<0.15) (Fig. 2D), demonstrating that the antibody was not directly affecting
HRGβ1 chemotaxis. This result indicates that HRGβ1-induced in vivo invasion is dependent
on the secretion of EGF within the primary tumor. In summary, these results indicate that
HRGβ1-mediated in vivo invasion of MTLn3-ErbB3 tumors is dependent on EGF/CSF-1
signaling within the primary tumor.
An ErbB2 transgenic model recapitulates the MTLn3-ErbB3 xenograft model of in vivo
invasion to HRGβ1
To determine whether HRGβ1 mediated in vivo invasion is dependent on EGF and CSF-1
signaling in other breast cancer models, we compared the MMTV-PyMT and MMTV-Neu
transgenic models (17,18). We have previously shown that HRGβ1 did not induce invasion of
MMTV-PyMT tumors (3), but MMTV-Neu tumors show high levels of expression of ErbB3
(17). Consistent with their ErbB3 expression, MMTV-Neu tumors showed enhanced in vivo
invasion in response to HRGβ1 (p<0.005) whereas MMTV-PyMT tumors did not (Fig. 3A).
We next tested the effect of blocking EGF and CSF-1 receptor signaling on HRGβ1-induced
in vivo invasion (Fig. 3B). Addition of the EGF neutralizing antibody (p<0.005) or CSF-1
receptor blocking antibody (p<0.005) resulted in inhibition of MMTV-Neu tumor invasion in
response to HRGβ1. We conclude that HRGβ1 stimulates in vivo invasion in MMTV-Neu
tumors also by activating the EGF/CSF-1 paracrine loop. To test how HRGβ1 could trigger
the EGF/CSF-1 paracrine loop we stimulated MMTV-Neu primary tumor cells in vitro with
HRGβ1 and tested the supernatants for CSF-1 secretion. Cultured Neu primary tumor cells
were stimulated for 4 hours with HRGβ1 (the same time used for the in vivo invasion assay),
and the supernatants were collected and assayed for the presence of CSF-1 protein using a
commercially available ELISA. There was a modest but significant increase in CSF-1 secretion
upon HRGβ1 stimulation of Neu tumor cells (ratio of HRGβ1 stimulated to buffer stimulated:
1.60+/−0.66, mean and standard deviation, N=6, p<.05). Thus, HRGβ1 induction of CSF-1
production could induce the EGF/CSF-1 paracrine loop.
CXCL12 mediated in vivo invasion in MMTV-PyMT tumors is also dependent on activation of
EGF/CSF-1 signaling
We had previously found that CXCL12 also induced in vivo invasion in MMTV-PyMT tumors
and that this invasive response could be blocked upon addition of Iressa (J. Wyckoff and D.
Cox, unpublished, Supplemental Fig. 2). Given our studies showing that HRGβ1-induced
invasion was dependent on the EGF/CSF-1 paracrine loop, we decided to test whether a
different type of ligand, such as CXCL12, which activates the G-protein coupled receptor
CXCR4, could also activate the EGF/CSF-1 paracrine loop. Similar to our results with
HRGβ1-induced invasion, both the neutralizing EGF antibody (p<0.005) and the CSF-1R
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blocking antibody (p<0.005) resulted in decreased in vivo invasion of MMTV-PyMT tumors
in response to CXCL12 (Fig. 4). To evaluate the contribution of macrophages to CXCL12 in
vivo invasion, MMTV-PyMT mice were injected with either empty or clodronate-containing
liposomes via tail vein 48 hours prior to measurement. Clodronate treatment resulted in
significantly reduced in vivo invasion to CXCL12 in PyMT tumors (the ratio of in vivo invasion
to CXCL12 in tumors pretreated with clodronate containing liposomes to empty liposomes
was 0.4 ±0.2, p<0.04).
CXCL12 and HRGβ1 signaling are not required for invasion in response to EGF
Given that CXCL12 and HRGβ1-induced invasion are dependent on EGF/CSF-1 signaling,
we then wished to determine whether EGF/CSF-1 induced invasion was in turn dependent
upon CXCL12 or HRGβ1. We first tested whether CXCL12 signaling was necessary for EGF/
CSF-1 in vivo invasion. We added the CXCR4 inhibitor AMD3100 (24) to needles containing
CXCL12 as a positive control to confirm that AMD3100 could block CXCL12 mediated in
vivo invasion from PyMT tumors. As expected, addition of AMD3100 resulted in inhibition
of CXCL12 mediated in vivo invasion from PyMT tumors (p<0.005) (Fig. 5A); however,
addition of AMD3100 to EGF containing needles did not result in impaired in vivo invasion
to EGF in PyMT tumors (p<0.4) (Fig. 5B). These results demonstrate that although CXCL12-
induced in vivo invasion is dependent on EGF/CSF-1 signaling, EGF-induced in vivo invasion
is not dependent on CXCL12 signaling.
Similarly, to test the role of HRGβ1 in EGF-induced in vivo invasion, we used an anti-ErbB3
blocking antibody. ErbB3 is the major receptor for HRGβ1 in MTLn3-ErbB3 cells (16), and
this antibody blocks the binding site for HRGβ1 on ErbB3. Addition of the ErbB3 blocking
antibody inhibited invasion of MTLn3-ErbB3 tumors to HRGβ1 (p<0.005) (Fig. 5C) but not
to EGF (p<0.4) (Fig. 5D), indicating that although HRGβ1-induced in vivo invasion is
dependent on EGF signaling, EGF-induced in vivo invasion is not dependent on HRGβ1.
DISCUSSION
We have previously shown that breast cancer cells invade surrounding breast tissue with the
help of macrophages (3). This process involves a paracrine communication loop between
cancer cells and macrophages in which cancer cells secrete CSF-1, a chemoattractant for
macrophages. Macrophages are in turn stimulated by CSF-1 and secrete EGF, a ligand that
binds to the EGF receptor in breast cancer cells and directs their chemotaxis (4). Within the
primary tumor, externally imposed gradients of EGF or CSF-1 will induce cancer cell and
macrophage invasion up the gradient. We report here for the first time that other ligand/receptor
systems can induce in vivo invasion responses that are dependent upon this EGF/CSF1
paracrine loop. Both a xenograft model (MTLn3-ErbB3 (16)) overexpressing the receptor for
heregulin, ErbB3, and a transgenic model (MMTV-Neu (17)) that expresses ErbB3, show
heregulin-induced invasion. This heregulin-induced invasion is dependent on macrophage
function as indicated by clodronate liposome inhibition, as well as by inhibition using a
blocking CSF-1R antibody. Both an EGFR-specific inhibitor, Iressa, as well as an anti-EGF
antibody, demonstrate that EGFR function and signaling via extracellular EGF are required
for the heregulin-induced invasion, but not for heregulin chemotaxis in vitro. A ligand for
CXCR4, CXCL12 (SDF-1), induced invasion effectively in the MMTV-PyMT model (which
showed no invasion in response to heregulin). CXCL12-induced in vivo invasion was also
dependent upon macrophage function, CSF-1R function, and extracellular EGF signaling.
While inhibition of the EGF/CSF-1 paracrine loop blocked in vivo invasion in response to
HRGβ1 and CXCL12, inhibition of either CXCR4 or ErbB3 did not block in vivo invasion
induced by EGF. These results demonstrate that the EGF/CSF-1 in vivo paracrine invasion
loop is independent of HRGβ1 and CXCL12, but can be triggered by these chemoattractants.
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Based on these results, we propose a novel model for in vivo invasion (Fig. 6), in which the
EGF/CSF-1 paracrine loop is an important driver of invasion within the primary tumor. In its
simplest form, invasion is induced by ligands of EGFR or CSF-1R present in the tumor
microenvironment, which directly feed into this “invasion engine”. In addition, if the tumor
cells (or potentially the macrophages) express other receptors such as ErbB3 or CXCR4, the
corresponding ligands such as heregulin or CXCL12 can activate the engine, which can then
dramatically enhance the invasion response to the ligand. Both CXCL12 and heregulin are
expressed in breast cancers (25–29). CXCL12 can be secreted by cancer-activated fibroblasts
(30,31) while heregulin has been reported to be expressed by endothelial cells (32–34). In
consequence, the invasion induced in response to the ligands secreted by these cells in the local
tumor microenvironment can contribute to enhanced intravasation and metastasis by directing
invasion out into the stroma and towards blood vessels. We have previously reported that the
MTLn3-ErbB3 cells show enhanced intravasation and metastasis (16), and CXCR4 has also
been reported to enhance breast cancer metastasis (11,35), consistent with this hypothesis.
However, not all ligands are able to trigger the invasion response in the models we have tested;
the macrophage chemoattractant VEGF did not induce invasion (3).
A clinical implication of these results is that inhibition of EGFR or CSF-1R signaling could
provide a broader inhibition of tumor cell invasiveness than might be anticipated based simply
on EGFR expression. EGFR expression levels in MTLn3 cells are slightly elevated (about
50,000 per cell (36)), but are not overexpressed to the level associated with typical EGFR
overexpressors such as the MDA-MB-231 cells (700,000 receptors per cell (37)) or MDA-
MB-468 cells (1.9 × 106 receptors per cell (38)). Similarly, CSF1R expression in MTLn3 cells
is low (4), and MTLn3 cells do not show CSF-1 induced lamellipod extension responses (data
not shown). Thus, our data suggest that invasion by breast tumors that do not show high EGFR
or CSF-1R expression can still be sensitive to inhibition of these receptors due to in vivo
paracrine interactions that can occur in the tumor microenvironment.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. HRGβ1 induces in vivo invasion of MTLn3-ErbB3 cells
A. Dose-response for HRGβ1-stimulated in vivo invasion in MTLn3-ErbB3 primary tumors
(p<.002 by ANOVA). B. In vivo invasion of MTLn3-ErbB3 (light gray) and MTLn3-pLXSN
(dark gray) primary tumors in response to 50nM HRGβ1 and 25nM EGF (p<.0004 for pLXSN
and p<.02 for ErbB3 by ANOVA). Means and standard deviations are shown.
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Figure 2. EGF/CSF-1 signaling is required for in vivo invasion of MTLn3-ErbB3 tumors in response
to HRGβ1 stimulation
A. In vivo invasion in response to 25 nM EGF or 50 nM HRGβ1 in the presence of a control
antibody, (IgG Ab), or a CSF-1 receptor-blocking antibody (CSF-1R Ab). B. The effect of
1μM Iressa or vehicle (DMSO) on in vivo invasion of MTLn3-ErbB3 primary tumors in
response to 50 nM HRGβ1. C. In vivo invasion in response to 25 nM EGF or 50 nM HRGβ1
in the presence of a control antibody, (IgG Ab), or an EGF-binding antibody (EGF Ab). D.
The effect of an EGF neutralizing antibody on chemotaxis of MTLn3-ErbB3 cells to 5 nM
EGF or 12.5 nM HRGβ1 determined using a Boyden chamber. Results are shown as the percent
of the chemotaxis response for each ligand remaining in the presence of the inhibitor compared
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to the chemotactic response for that ligand in the absence of the inhibitor. Means and standard
deviations are shown. Pairwise comparisons by t-test are provided in the text.
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Figure 3. MMTV-Neu tumors show in vivo invasion in response to HRGβ1 which requires EGF/
CSF-1 signaling
A. MMTV-PyMT (dark gray) and MMTV-Neu (light gray) tumors were tested for their ability
to invade in vivo in response to 50 nM HRGβ1. B. MMTV-Neu tumor in vivo invasive response
to 50 nM HRGβ1 in the presence of either control antibody (IgG Ab), an EGF neutralizing
antibody (EGF Ab) or a CSF-1 R blocking antibody (CSF-1R Ab) (p<5×10−13 by ANOVA).
Means and standard deviations are shown.
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Figure 4. MMTV-PyMT tumors invade in vivo in response to CXCL12 stimulation and this invasion
is dependent on EGF/CSF-1 signaling and macrophages
In vivo invasion of MMTV-PyMT tumors in response to 62.5 nM CXCL12 in the presence of
a control antibody (IgG Ab), a CSF-1 receptor antibody (CSF-1R Ab), or an EGF neutralizing
antibody (EGF Ab) (p< 2 × 10−8 by ANOVA). Means and standard deviations are shown.
Hernandez et al. Page 15
Cancer Res. Author manuscript; available in PMC 2010 April 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 5. EGF induced in vivo invasion is not dependent on CXCL12 or HRGβ1 signaling
A. The effect of CXCR4 inhibition (AMD3100, 100 nM) on invasion of MMTV-PyMT tumors
in response to 62.5 nM CXCL12. B. The effect of CXCR4 inhibition (AMD3100, 100 nM) on
invasion of MMTV-PyMT tumors in response to EGF. C. In vivo invasion of MTLn3-ErbB3
tumors to 50 nM HRGβ1 in the presence of a control antibody (IgG Ab), or an ErbB3 blocking
antibody (ErbB3 Ab). D. In vivo invasion of MTLn3-ErbB3 tumors to 25 nM EGF in the
presence of a control antibody (IgG Ab), or an ErbB3 blocking antibody (ErbB3 Ab). Means
and standard deviations are shown. Pairwise comparisons by t-test are provided in the text.
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Figure 6. Model for in vivo invasion
The primary tumor expresses receptors for a number of chemoattractants, including the EGF
receptor. Chemoattractants present in the tumor microenvironment can feed into the EGF/
CSF-1 paracrine loop, which then drives invasion in vivo.
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